vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and PETMED EXPRESS INC (PETS). Click either name above to swap in a different company.
PETMED EXPRESS INC is the larger business by last-quarter revenue ($40.7M vs $37.2M, roughly 1.1× GYRE THERAPEUTICS, INC.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -26.0%, a 22.3% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -23.3%). GYRE THERAPEUTICS, INC. produced more free cash flow last quarter ($-5.8M vs $-9.2M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -20.9%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.
GYRE vs PETS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $40.7M |
| Net Profit | $-1.4M | $-10.6M |
| Gross Margin | 95.3% | 23.3% |
| Operating Margin | 0.3% | -25.7% |
| Net Margin | -3.7% | -26.0% |
| Revenue YoY | 33.4% | -23.3% |
| Net Profit YoY | -340.1% | -1392.6% |
| EPS (diluted) | $-0.01 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $40.7M | ||
| Q3 25 | $30.6M | $44.4M | ||
| Q2 25 | $26.8M | $51.2M | ||
| Q1 25 | $22.1M | $50.8M | ||
| Q4 24 | $27.9M | $52.0M | ||
| Q3 24 | $25.5M | $58.0M | ||
| Q2 24 | $25.2M | $66.2M | ||
| Q1 24 | $27.2M | $65.1M |
| Q4 25 | $-1.4M | $-10.6M | ||
| Q3 25 | $5.9M | $-8.5M | ||
| Q2 25 | $1.6M | $-34.2M | ||
| Q1 25 | $3.7M | $-11.6M | ||
| Q4 24 | $569.0K | $-707.0K | ||
| Q3 24 | $2.9M | $2.3M | ||
| Q2 24 | $4.5M | $3.8M | ||
| Q1 24 | $9.9M | $-5.0M |
| Q4 25 | 95.3% | 23.3% | ||
| Q3 25 | 94.7% | 28.0% | ||
| Q2 25 | 95.7% | 28.1% | ||
| Q1 25 | 95.9% | 29.9% | ||
| Q4 24 | 95.8% | 31.0% | ||
| Q3 24 | 96.2% | 32.3% | ||
| Q2 24 | 96.9% | 28.8% | ||
| Q1 24 | 96.4% | 29.3% |
| Q4 25 | 0.3% | -25.7% | ||
| Q3 25 | 22.7% | -18.9% | ||
| Q2 25 | 8.1% | -66.7% | ||
| Q1 25 | 10.3% | -11.9% | ||
| Q4 24 | 2.4% | -0.9% | ||
| Q3 24 | 16.6% | 1.0% | ||
| Q2 24 | 12.7% | 6.6% | ||
| Q1 24 | 29.7% | -5.9% |
| Q4 25 | -3.7% | -26.0% | ||
| Q3 25 | 19.4% | -19.2% | ||
| Q2 25 | 5.9% | -66.7% | ||
| Q1 25 | 16.9% | -22.9% | ||
| Q4 24 | 2.0% | -1.4% | ||
| Q3 24 | 11.2% | 4.0% | ||
| Q2 24 | 18.0% | 5.7% | ||
| Q1 24 | 36.6% | -7.7% |
| Q4 25 | $-0.01 | $-0.50 | ||
| Q3 25 | $0.03 | $-0.41 | ||
| Q2 25 | $0.00 | $-1.65 | ||
| Q1 25 | $0.00 | $-0.56 | ||
| Q4 24 | $0.00 | $-0.03 | ||
| Q3 24 | $0.01 | $0.11 | ||
| Q2 24 | $0.01 | $0.18 | ||
| Q1 24 | $0.03 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $26.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $32.8M |
| Total Assets | $166.1M | $88.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $26.9M | ||
| Q3 25 | $60.0M | $36.1M | ||
| Q2 25 | $54.4M | $41.1M | ||
| Q1 25 | $29.9M | $54.7M | ||
| Q4 24 | $26.7M | $50.1M | ||
| Q3 24 | $25.1M | $52.0M | ||
| Q2 24 | $25.1M | $46.0M | ||
| Q1 24 | $37.4M | $55.3M |
| Q4 25 | $106.0M | $32.8M | ||
| Q3 25 | $101.9M | $43.1M | ||
| Q2 25 | $92.0M | $51.5M | ||
| Q1 25 | $68.1M | $85.1M | ||
| Q4 24 | $63.3M | $96.2M | ||
| Q3 24 | $63.2M | $96.4M | ||
| Q2 24 | $60.4M | $93.5M | ||
| Q1 24 | $56.6M | $96.7M |
| Q4 25 | $166.1M | $88.0M | ||
| Q3 25 | $159.4M | $100.3M | ||
| Q2 25 | $152.6M | $109.8M | ||
| Q1 25 | $129.8M | $148.7M | ||
| Q4 24 | $125.4M | $144.8M | ||
| Q3 24 | $125.2M | $146.0M | ||
| Q2 24 | $120.9M | $152.7M | ||
| Q1 24 | $122.0M | $169.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $-9.2M |
| Free Cash FlowOCF − Capex | $-5.8M | $-9.2M |
| FCF MarginFCF / Revenue | -15.5% | -22.7% |
| Capex IntensityCapex / Revenue | 0.4% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $-23.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $-9.2M | ||
| Q3 25 | $4.7M | $-2.2M | ||
| Q2 25 | $2.1M | $-12.3M | ||
| Q1 25 | $-129.0K | $7.0M | ||
| Q4 24 | $-2.8M | $-1.2M | ||
| Q3 24 | $1.7M | $7.4M | ||
| Q2 24 | $-5.5M | $-8.5M | ||
| Q1 24 | $2.9M | $7.1M |
| Q4 25 | $-5.8M | $-9.2M | ||
| Q3 25 | $4.0M | $-4.8M | ||
| Q2 25 | $1.8M | $-13.6M | ||
| Q1 25 | $-251.0K | $4.6M | ||
| Q4 24 | $-2.8M | $-1.9M | ||
| Q3 24 | $1.0M | $6.1M | ||
| Q2 24 | $-6.9M | $-9.2M | ||
| Q1 24 | $2.7M | $5.9M |
| Q4 25 | -15.5% | -22.7% | ||
| Q3 25 | 13.1% | -10.8% | ||
| Q2 25 | 6.8% | -26.5% | ||
| Q1 25 | -1.1% | 9.1% | ||
| Q4 24 | -10.1% | -3.7% | ||
| Q3 24 | 4.1% | 10.6% | ||
| Q2 24 | -27.5% | -13.9% | ||
| Q1 24 | 9.8% | 9.0% |
| Q4 25 | 0.4% | 0.1% | ||
| Q3 25 | 2.2% | 5.9% | ||
| Q2 25 | 1.0% | 2.5% | ||
| Q1 25 | 0.6% | 4.7% | ||
| Q4 24 | 0.2% | 1.5% | ||
| Q3 24 | 2.7% | 2.2% | ||
| Q2 24 | 5.8% | 1.0% | ||
| Q1 24 | 0.9% | 1.9% |
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | -4.85× | — | ||
| Q3 24 | 0.60× | 3.18× | ||
| Q2 24 | -1.21× | -2.27× | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GYRE
Segment breakdown not available.
PETS
| Reorder | $34.0M | 84% |
| New Order | $5.0M | 12% |
| Membership Fees | $1.6M | 4% |
